Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Identification of a possible proteomic Biomarker in Parkinson’s Disease: Discovery and Replication in Blood, brain and CSF

Journal article

WINCHESTER L. and NEVADO-HOLGADO A., (2022), Brain Communications

Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT

Journal article

Howard R. et al, (2020), Efficacy and Mechanism Evaluation, 7, 1 - 62

Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma.

Journal article

Lovestone S. and Manji HK., (2020), Clin Pharmacol Ther, 107, 79 - 81

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.

Journal article

Ten Kate M. et al, (2018), Alzheimers Res Ther, 10

Heterogeneous patterns of brain atrophy in Alzheimer's disease.

Journal article

Poulakis K. et al, (2018), Neurobiol Aging, 65, 98 - 108

Imaging Aβ and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451.

Journal article

Firouzian A. et al, (2018), EJNMMI Res, 8

Load More